

# Michael P Pollastri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2367528/publications.pdf>

Version: 2024-02-01

66  
papers

1,996  
citations

201658

27  
h-index

276858

41  
g-index

83  
all docs

83  
docs citations

83  
times ranked

2929  
citing authors

#	ARTICLE	IF	CITATIONS
1	Physiologic Targets and Modes of Action for CBL0137, a Lead for Human African Trypanosomiasis Drug Development. <i>Molecular Pharmacology</i> , 2022, 102, 1-16.	2.3	2
2	Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9404-9430.	6.4	6
3	Application of $\alpha$ -Threonine Aldolase to on-DNA Reactions. <i>Bioconjugate Chemistry</i> , 2021, 32, 1973-1978.	3.6	4
4	Hit-to-Lead Optimization of Benzoxazepinoindazoles As Human African Trypanosomiasis Therapeutics. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2527-2546.	6.4	11
5	Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5- <i>b</i> ]pyridazines for the Treatment of Human African Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 756-783.	6.4	10
6	Medicinal Chemistry Optimization of a Diaminopurine Chemotype: Toward a Lead for <i>Trypanosoma brucei</i> Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9912-9927.	6.4	5
7	Structure–property studies of an imidazoquinoline chemotype with antitrypanosomal activity. <i>RSC Medicinal Chemistry</i> , 2020, 11, 950-959.	3.9	3
8	Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 249-257.	2.8	17
9	Structure–Bioactivity Relationships of Lapatinib Derived Analogs against <i>Schistosoma mansoni</i> . <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 258-265.	2.8	2
10	Evaluation of a class of isatinoids identified from a high-throughput screen of human kinase inhibitors as anti-Sleeping Sickness agents. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007129.	3.0	4
11	Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 665-687.	6.4	23
12	Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon. <i>Trends in Parasitology</i> , 2018, 34, 178-179.	3.3	39
13	Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of <i>Plasmodium falciparum</i> Proliferation. <i>ACS Infectious Diseases</i> , 2018, 4, 577-591.	3.8	12
14	Calcium-Dependent Protein Kinase 5 Is Required for Release of Egress-Specific Organelles in <i>Plasmodium falciparum</i> . <i>MBio</i> , 2018, 9, .	4.1	56
15	The Importance of Collaboration between Industry, Academics, and Nonprofits in Tropical Disease Drug Discovery. <i>ACS Infectious Diseases</i> , 2018, 4, 445-448.	3.8	13
16	Anilinoquinoline based inhibitors of trypanosomatid proliferation. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006834.	3.0	7
17	Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 996-1001.	2.8	9
18	From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis. <i>ACS Infectious Diseases</i> , 2017, 3, 225-236.	3.8	19

#	ARTICLE	IF	CITATIONS
19	Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 350-354.	2.8	21
20	Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation. <i>European Journal of Medicinal Chemistry</i> , 2017, 141, 446-459.	5.5	18
21	Novel Effects of Lapatinib Revealed in the African Trypanosome by Using Hypothesis-Generating Proteomics and Chemical Biology Strategies. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	8
22	Fluorinated Adenosine A2A Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics. <i>International Journal of Medicinal Chemistry</i> , 2017, 2017, 1-8.	2.2	5
23	The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite <i>Giardia lamblia</i> represents a potential drug target. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005891.	3.0	16
24	Glycogen Synthase Kinase 3 $\beta$ Promotes the Endocytosis of Transferrin in the African Trypanosome. <i>ACS Infectious Diseases</i> , 2016, 2, 518-528.	3.8	12
25	Identification of "Preferred" Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing?. <i>ACS Infectious Diseases</i> , 2016, 2, 180-186.	3.8	28
26	Repurposing strategies for tropical disease drug discovery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2569-2576.	2.2	83
27	Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis. <i>Scientific Reports</i> , 2016, 6, 32083.	3.3	27
28	The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 189-201.	6.1	88
29	Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5522-5537.	6.4	56
30	Repurposing Human PDE4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE4 Inhibitor GSK-256066 as Inhibitors of PDEB1 of <i>Trypanosoma brucei</i> . <i>Chemical Biology and Drug Design</i> , 2015, 85, 549-564.	3.2	14
31	Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1). <i>Tetrahedron Letters</i> , 2015, 56, 2832-2835.	1.4	44
32	Ligand deconstruction: Why some fragment binding positions are conserved and others are not. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2585-94.	7.1	61
33	Evaluation of aromatic 6-substituted thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, leishmaniasis, and malaria. <i>MedChemComm</i> , 2015, 6, 339-346.	3.4	32
34	A Target Repurposing Approach Identifies N-myristoyltransferase as a New Candidate Drug Target in Filarial Nematodes. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3145.	3.0	20
35	Identification and Characterization of Hundreds of Potent and Selective Inhibitors of <i>Trypanosoma brucei</i> Growth from a Kinase-Targeted Library Screening Campaign. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3253.	3.0	47
36	Finding New Collaboration Models for Enabling Neglected Tropical Disease Drug Discovery. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2866.	3.0	10

#	ARTICLE	IF	CITATIONS
37	Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery. <i>MedChemComm</i> , 2014, 5, 655-658.	3.4	42
38	A chemical screen identifies small molecules that regulate hepcidin expression. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 231-240.	1.4	18
39	Repurposing human PDE4 inhibitors for neglected tropical diseases: Design, synthesis and evaluation of cilomilast analogues as <i>Trypanosoma brucei</i> PDEB1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4084-4089.	2.2	26
40	Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites. <i>Chemical Reviews</i> , 2014, 114, 11280-11304.	47.7	55
41	Establishment of a Structure-Activity Relationship of 1-Imidazo[4,5-c]quinoline-Based Kinase Inhibitor NVP-BEZ235 as a Lead for African Sleeping Sickness. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4834-4848.	6.4	35
42	In Silico Identification of an Aryl Hydrocarbon Receptor Antagonist with Biological Activity In Vitro and In Vivo. <i>Molecular Pharmacology</i> , 2014, 86, 593-608.	2.3	45
43	Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives IL-22 Production. <i>PLoS ONE</i> , 2014, 9, e87877.	2.5	106
44	The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 777-784.	5.5	44
45	Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5971-5974.	2.2	8
46	Antitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of <i>Trypanosoma cruzi</i> CYP51 and Parasite Growth. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2556-2567.	6.4	60
47	Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3820-3832.	6.4	66
48	Jumping the industrial-academia fence. <i>Future Medicinal Chemistry</i> , 2013, 5, 25-26.	2.3	0
49	Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds. <i>PLoS ONE</i> , 2013, 8, e56150.	2.5	36
50	Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2582-2584.	2.2	25
51	Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2579-2581.	2.2	23
52	Target repurposing for neglected diseases. <i>Future Medicinal Chemistry</i> , 2011, 3, 1307-1315.	2.3	75
53	Pharmacological Validation of <i>Trypanosoma brucei</i> Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping Sickness. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 8188-8194.	6.4	46
54	The Future of Drug Repositioning. <i>Annual Reports in Medicinal Chemistry</i> , 2011, 46, 385-401.	0.9	29

#	ARTICLE	IF	CITATIONS
55	The challenge of developing robust drugs to overcome resistance. <i>Drug Discovery Today</i> , 2011, 16, 755-61.	6.4	21
56	The Susceptibility of Trypanosomatid Pathogens to PI3/mTOR Kinase Inhibitors Affords a New Opportunity for Drug Repurposing. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1297.	3.0	70
57	Neutralizing Positive Charges at the Surface of a Protein Lowers Its Rate of Amide Hydrogen Exchange without Altering Its Structure or Increasing Its Thermostability. <i>Journal of the American Chemical Society</i> , 2010, 132, 17411-17425.	13.7	29
58	Overview on the Rule of Five. <i>Current Protocols in Pharmacology</i> , 2010, 49, Unit 9.12.	4.0	108
59	Identification and Characterization of Kava-derived Compounds Mediating TNF- $\alpha$ Suppression. <i>Chemical Biology and Drug Design</i> , 2009, 74, 121-128.	3.2	28
60	Efficient Use of the Iron Ortho-Nitrophenylporphyrin Chloride to Mimic Biological Oxidations of Dimethylaminoantipyrene. <i>Chemical Biology and Drug Design</i> , 2007, 70, 354-359.	3.2	9
61	The conversion of alcohols to halides using a filterable phosphine source. <i>Tetrahedron Letters</i> , 2001, 42, 2459-2460.	1.4	23
62	Synthesis, structure, and thermal properties of 1,2-dipalmitoylgallylglycerol (DPGG), a novel self-adhering lipid. <i>Chemistry and Physics of Lipids</i> , 2000, 104, 67-74.	3.2	8
63	Polyphenols Increase Adhesion Between Lipid Bilayers by Forming Interbilayer Bridges. , 1999, 66, 451-470.		2
64	2-Benzoylbenzoic Acid: A Photolabile Mask for Alcohols and Thiols. <i>Journal of Organic Chemistry</i> , 1996, 61, 9455-9461.	3.2	51
65	Cis-3,5-dimethyl-3,5-piperidinedicarboxylic acid, an amino diacid variant of Kemp's triacid. <i>Tetrahedron Letters</i> , 1994, 35, 4515-4518.	1.4	7
66	Loss of the tert-butyloxycarbonyl (Boc) protecting group under basic conditions. <i>Tetrahedron Letters</i> , 1994, 35, 5409-5412.	1.4	40